Treatment of refractory mastocytic enterocolitis with budesonide.
J Gastrointestin Liver Dis
; 27(3): 327-329, 2018 Sep.
Article
in En
| MEDLINE
| ID: mdl-30240478
Mast cells (MCs) are being increasingly implicated as a possible contributor to symptoms in diarrhea predominant irritable bowel syndrome (IBS). The term "mastocytic enterocolitis" was proposed to describe an increase in mucosal MCs in patients with chronic diarrhea due to functional gastrointestinal disease (FGID). The efficacy of anti-MC mediator therapy (antihistamines and MC stabilizers) has been well documented in this setting. Here we describe the treatment with oral budesonide of mastocytic enterocolitis refractory to standard anti-MC therapy.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Mastocytosis
/
Adrenal Cortex Hormones
/
Budesonide
/
Mast Cells
Type of study:
Diagnostic_studies
Limits:
Adult
/
Humans
/
Male
Language:
En
Journal:
J Gastrointestin Liver Dis
Journal subject:
GASTROENTEROLOGIA
Year:
2018
Document type:
Article
Affiliation country:
United States
Country of publication:
Romania